Harvard Stem Cell Institute Wins $25 Million Investment From GlaxoSmithKline
Luke Timmerman7/25/08
GlaxoSmithKline, the world’s second-biggest drugmaker, said it agreed to invest $25 million over five years in the Harvard Stem Cell Institute for a collaboration to develop new treatments. London-based Glaxo (NYSE: GSK) said the collaboration will spur research at Harvard and at least four affiliated hospitals to study neuroscience, cancer, diabetes, obesity and musculoskeletal diseases. “We have carefully chosen the Boston biomedical community to collaborate with on this important venture. It has the highest concentration of leading stem cell scientists,” GSK’s head of drug discovery, Patrick Vallance, said in a statement.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
